ライフサイエンスコーパス: juvenile dermatomyositis

1 in some human autoimmune settings including juvenile dermatomyositis.

2 n muscle tissue of adult dermatomyositis and juvenile dermatomyositis.

3 portant contributions to the pathogenesis of juvenile dermatomyositis.

4 te or ciclosporin in children with new-onset juvenile dermatomyositis.

5 ematosus, juvenile idiopathic arthritis, and juvenile dermatomyositis.

6 of genetic control of the immune response in juvenile dermatomyositis.

7 tion and small vessel occlusion in untreated juvenile dermatomyositis.

8 mononuclear cells from children with active juvenile dermatomyositis.

9 evels, and genetics play in the evolution of juvenile dermatomyositis.

10 ces in understanding the etiopathogenesis of juvenile dermatomyositis.

11 ients with juvenile idiopathic arthritis and juvenile dermatomyositis.

12 iation between anti-flagellin antibodies and juvenile dermatomyositis.

13 s included 3 pairs of monozygotic twins with juvenile dermatomyositis, 11 families with other sibling

14 Patients with juvenile dermatomyositis, a systemic autoimmune disease,

15 Children and adolescents with juvenile dermatomyositis and systemic lupus erythematosu

16 Intravenous cyclophosphamide in refractory juvenile dermatomyositis and tacrolimus ointment for the

17 molecular genetics of children affected with juvenile dermatomyositis and the impact these genes have

18 isease entities, but is primarily made up of juvenile dermatomyositis and, to a lesser degree, juveni

19 kine-specific information from children with juvenile dermatomyositis, and includes pertinent data fr

20 Systemic lupus erythematosus, juvenile dermatomyositis, and juvenile localized sclerod

21 t incidence of systemic lupus erythematosus, juvenile dermatomyositis, and other primary systemic vas

22 ermatomyositis (anti-SAE autoantibodies) and juvenile dermatomyositis (anti-p155/140 autoantibodies)

23 st data for treatment of dermatomyositis and juvenile dermatomyositis are from anecdotal, non-randomi

24 I major histocompatibility complex in early juvenile dermatomyositis are reported.

25 We sequenced peptides eluted from the juvenile dermatomyositis-associated class II allele HLA-

26 Juvenile dermatomyositis (DM) is a chronic inflammatory

27 Juvenile dermatomyositis (DM) is an autoimmune disease o

28 Except when the diagnosis of juvenile dermatomyositis (DM) is in doubt, a case has no

29 he identification of novel autoantibodies in juvenile dermatomyositis (DM) may have etiologic and cli

30 h before symptom onset and the prevalence of juvenile dermatomyositis (DM), compared to juvenile poly

31 BMD) in patients at the time of diagnosis of juvenile dermatomyositis (DM), to compare the RANKL:oste

32 ) has been implicated in the pathogenesis of juvenile dermatomyositis (DM).

33 ) are constituents of muscle inflammation in juvenile dermatomyositis (DM).

34 amples obtained from children diagnosed with juvenile dermatomyositis (DM).

35 Type I interferon activity in juvenile dermatomyositis has been demonstrated by both g

36 We have previously shown that juvenile dermatomyositis is associated with the HLA-DQA1

37 Juvenile dermatomyositis is the most common of the idiop

38 many connective-tissue diseases, especially juvenile dermatomyositis (JDM) and systemic sclerosis; h

39 Juvenile dermatomyositis (JDM) is a multisystem autoimmu

40 Juvenile dermatomyositis (JDM) is a rare immune-mediated

41 Juvenile dermatomyositis (JDM) is a rare, severe autoimm

42 Juvenile dermatomyositis (JDM) is an immune-mediated inf

43 raviolet radiation exposure 1 month prior to juvenile dermatomyositis (JDM) may trigger the onset of

44 Juvenile dermatomyositis (JDM), the most common pediatri

45 In juvenile dermatomyositis (JDM), the most common pediatri

46 Juvenile dermatomyositis (JDM), the most common pediatri

47 iation and have been found in high levels in juvenile dermatomyositis (JDM), which may account the fr

48 ocusing on how to assess the many aspects of juvenile dermatomyositis (JDM).

49 ation with disease activity in children with Juvenile Dermatomyositis (JDM).

50 deposits develop in 20-40% of children with juvenile dermatomyositis (juvenile DM), contributing to

51 pus erythematosis, Wegener's granulomatosis, juvenile dermatomyositis, juvenile scleroderma and autoi

52 cleroderma, mixed connective tissue disease, juvenile dermatomyositis, juvenile spondyloarthropathy a

53 of disease, immunotherapies to better treat juvenile dermatomyositis may become available in the fut

54 ficantly from that of p155 antibody-negative juvenile dermatomyositis patients (P = 0.003).

55 Juvenile dermatomyositis patients with p155 autoantibody

56 rosis factor-alpha synthesis is increased in juvenile dermatomyositis patients with the tumor necrosi

57 In juvenile dermatomyositis, peptides from human skeletal m

58 ered prednisone plus methotrexate achieved a juvenile dermatomyositis PRINTO 20 improvement (p=0.0228

59 were the proportion of patients achieving a juvenile dermatomyositis PRINTO 20 level of improvement

60 s pediatric systemic lupus erythematosus and juvenile dermatomyositis, remain life-threatening.

61 hritis and Musculoskeletal and Skin Diseases Juvenile Dermatomyositis Research Registry and the Natio

62 tment for the dermatologic manifestations of juvenile dermatomyositis seem promising.

63 ever, preliminary gene expression studies in juvenile dermatomyositis, systemic lupus erythematosus,

64 dvances in understanding these mechanisms in juvenile dermatomyositis, the most common form of childh

65 In juvenile dermatomyositis, the quantitative magnetic reso

66 ents aged 18 years or younger with new-onset juvenile dermatomyositis who had received no previous tr

67 tumor necrosis factor-alpha, more common in juvenile dermatomyositis with the tumor necrosis factor-

68 ematosus, juvenile idiopathic arthritis, and juvenile dermatomyositis, with special interest on strat